secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tourmaline Bio, Inc. (—)
CIK:        0001827506
Form:       8-K
Filed at:   2023-10-20T23:59:59+00:00
Accession:  0001193125-23-259403
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.95
Item codes: 2.01, 1.01, 5.02, 3.03, 5.01, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tourmaline Bio completes reverse merger with Talaris; 78.1% ownership to former Tourmaline holders
--------------------------------------------------------------------------------

- Merger closed Oct. 19, 2023; Tourmaline survived as wholly owned sub, renamed Tourmaline Bio, Inc.
- Reverse stock split 1-for-10 effected at 4:00 p.m. ET; new CUSIP 89157D 105.
- Former Tourmaline stockholders receive ~15.9M shares (0.7977 exchange ratio, pre-split); own 78.1% of post-merger company.
- New board of 7 directors: 2 from legacy Talaris, 5 from Tourmaline; Sandeep Kulkarni named CEO.
- Common stock trades on Nasdaq under new ticker TRML starting Oct. 20, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1827506/000119312523259403/0001193125-23-259403-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1827506/000119312523259403/d571384d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-259403

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer